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  Abstract  
Genetics has long been considered to associate with many exer-
cise-related traits and sport performance phenotypes. A genetic 
basis for elite international marathon running performance exists 
due to the heritability of endurance-related traits. This has 
prompted a generation of genomic study to identify marathon suc-
cess. The aim of this study was to systematically review the evi-
dence of genes, and their polymorphisms, that may play a role in 
marathon running performance. A search strategy was imple-
mented on systematic databases following PRISMA guidelines. 
Studies were case-control, cohort or genome-wide association de-
signs and provided data on the genotypes associated with elite 
marathon athlete status and/or marathon running performance. 
The search identified 241 studies, from which, 14 studies were 
deemed suitable for inclusion. A total of 160 different polymor-
phisms in 27 genes were identified in 10,442 participants, of 
which 2,984 were marathon distance runners. The review identi-
fied a possible 16 single nucleotide polymorphisms (SNPs) in 14 
genes associated with marathon running performance. While 
multiple genes and their polymorphisms have been associated 
with marathon running performance, predicting future marathon 
success based on genomic data is premature due to the lack of 
replicated studies. There is limited replication of genotype-phe-
notype associations and there is possible publication bias, thus, 
further studies are required to strengthen our understanding of the 
genes involved in marathon running. Future research utilising ge-
nome-wide technologies in large cohorts is required to elucidate 
the multiple genetic factors that govern complex endurance-re-
lated traits and the impact of epigenetics should be considered.  
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type.
  
Introduction 
 
Marathon running is predominantly determined by maxi-
mal oxygen uptake (Vሶ O2 max), lactate threshold, running 
economy and oxygen uptake kinetics (Joyner and Coyle, 
2008). It has been acknowledged that to reach elite-level 
performance a synergy of physiological and psychological 
traits, combined with an optimal environment are required 
(Tucker et al., 2013). Physiological parameters of herita-
bility such as Vሶ O2 max for endurance performance indicate 
significant genetic components. For example, Bouchard et 
al. (1999) demonstrated that the heritability of Vሶ O2max 
falls in the range of 40-50%, indicating such parameters 
present a considerable genetic influence. In addition, elite 
marathon runners of Kenyan or Ethiopian descent account 
for 90 of the top 100 marathon running performances of all 
time and hold the six previous world records (International 
Association of Athletics Federations, 2018). Based on this 
geographical concentration of unparalleled success, asser-
tions of a genetic endowment for marathon running perfor-
mance have been further amplified (Tuker et al., 2013; 
Vancini et al., 2014). Therefore, a major focus of sport ge-
nomics has been to identify specific genes and their poly-
morphisms associated with elite-level performance to fa-
cilitate in the identification of future athletic talent (Roth, 
2012; Popovski et al., 2016). Specifically, one gene that 
has been extensively studied due to its associated role in 
endurance performance is angiotensin I-converting en-
zyme (ACE) (Gayagay et al., 1998; Montgomery et al., 
1998). The ACE gene functional polymorphism is based 
on either the presence (insertion [I]) or absence (deletion 
[d]) of an intron sequence. The insertion (I) allele has been 
positively associated with elite endurance running perfor-
mance in Caucasians due to lower circulating and tissue 
ACE activity (Myserson et al., 1999). No significant dif-
ferences in the ACE I/deletion (D) genotype were found 
between Kenyan elite marathon runners and their respec-
tive general population (Scott et al., 2005). This ethnic dis-
parity led to the contention that the East African running 
phenomenon is not a genetically mediated one (Wilber & 
Pitsiladis, 2012). On the contrary, the existing research to 
date, may be interpreted as evidence for the polygenic na-
ture of complex endurance-related traits, due to the basis of 
researching the broader context of endurance performance, 
but also highlighting the limitations of a single candidate 
gene approach (Ahmetov et al., 2016). Furthermore, the 
use of case-control studies has given rise to inconsistent 
findings (Drozdovska et al., 2013; Tural et al., 2014), 
which may be attributed to small sample sizes resulting in 
insufficient statistical power to demonstrate significant ef-
fects of numerous genes each with small contributions 
(Wang et al., 2013). Where previous studies have been con-
ducted on general endurance performance rather than spe-
cific to elite marathon running, ensuring sufficient statisti-
cal power is a particular challenge in elite-level perfor-
mance since elite athletes are by definition, limited to a 
small number of superior individuals. Therefore, it has 
been suggested that the impact of these issues can be re-
duced by pooling single studies into a meta-analysis 
(Lopez-Leon et al., 2016). To date, meta-analyses have 
confirmed the associations of ACE and peroxisome prolif-
erator-activated receptor alpha (PPARα) genes with endur- 
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ance performance (Ma et al., 2013; Lopez-Leon et al., 
2016). However, it has been suggested that at least 93 ge-
netic markers are associated with elite endurance athletic 
status (Ahmetov et al., 2016). Yet, to date, no review has 
identified the genetic markers associated specifically to 
elite marathon running per se. 
Therefore, the objectives of the current systematic 
review were to critically examine the evidence concerning 
genes that may play a role in the performance of elite-level 
international marathon athletes, and to provide insight into 
the predictive utility of genetic testing in identifying future 
marathon success. This investigation of multiple genes, 
and their polymorphisms, is advantageous as it allows a 
more comprehensive picture of genotype-phenotype rela-
tionships to emerge, thus improving the future application 
of genomics as a practical tool in marathon talent identifi-
cation. 
 
Methods 
 
Search strategy 
A published literature search that investigated the associa-
tion between genes and marathon performance was con-
ducted up to May 2018 and obtained according to the Pre-
ferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines (Moher et al., 2009). A 
predetermined search strategy was conducted on system-
atic databases for publications indexed in PubMed, 
SPORTDiscus and Google Scholar using combinations of 
the following search terms: “genes” OR “genetics” OR 
“genomics” AND “marathon” OR “endurance” OR “elite 
performance” in the titles of papers. Additional publica-
tions were also considered by cross-referencing. A hand 
search of the reference lists of articles included in the final 
analysis that were identified via the database search was 
conducted, as were the first 20 “related articles” of those 
included database search articles on PubMed.  
 
Study selection 
All publications retrieved were screened by title and any 
duplicates or those irrelevant to the research question were 
removed. Abstracts of the remaining studies were then sim-
ilarly screened and 24 studies were selected for full-text 
assessment against the predetermined inclusion and exclu-
sion criteria outlined below.  
 
Inclusion and exclusion criteria  
The present review included case-control, cohort and ge-
nome-wide association studies (GWAS). To be included, 
studies were required to provide data on the genotypes as-
sociated with elite international marathon athlete status 
and/or marathon running performance published in peer-
review journals. Those studies identified as ‘elite’ were 
based on participants having been international competi-
tors and/or national representatives in the marathon dis-
tance as determined by entry standards from the Interna-
tional Association of Athletics Federations (IAAF, 2018). 
There were no restrictions applied regarding the age, gen-
der or ethnicity of the participants. Studies were excluded 
if they were: (i) review articles, congress abstracts, editori-
als or other non-original articles; (ii) reported in a language 
other than English. Overall, 14 studies were included for 
qualitative synthesis. The study selection process and rea-
sons for exclusion are illustrated in Figure 1.  
Studies were assessed for inclusion by two inde-
pendent reviewers, RK and DF, with disagreements re-
solved by discussion, and arbitration (HJM) if necessary. 
The reviewers, RK and DF were not blinded to authors, in-
stitutions or journals of publication. If a decision on 
whether to include or exclude a paper could not be made 
from the title and abstract, full text was obtained and 
checked.  
 
Data extraction and quality assessment 
For all selected studies, the following data were extracted: 
(i) first author name; (ii) publication date; (iii) participant 
characteristics; (iv) study design; (v) genetic markers 
measured; (vi) allelic frequencies; and (vii) bias. These 
outcomes were extracted for the narrative review. 
 
Risk of bias assessment  
The risk of bias of individual studies was assessed using 
the Cochrane Collaboration’s risk of bias tool (RoB 2.0; 
Higgins et al., 2016). Studies were given an overall risk of 
bias grade of either “high”, “some” or “low” calculated 
from the following five domains: a) sequence generation, 
b) allocation concealment, c) blinding, d) missing outcome 
data, e) selective reporting of results. If details for a partic-
ular domain were insufficient, the risk of bias was assessed 
as “unclear”. Assessments were performed independently 
by two authors (RK and DF) with disagreements resolved 
by discussion, and arbitration (HJM) if necessary. Compo-
nents were assessed independently, as per PRISMA 
(Moher et al., 2009) and Cochrane collaboration (Higgins 
et al., 2016) recommendations. 
 
Data synthesis 
Qualitative analysis was carried out on the studies selected 
focusing on the association between genetic markers, elite 
marathon athlete status and running performance. A narra-
tive review was provided in text and tables to summarise 
study characteristics. If deemed appropriate, a meta-analy-
sis was planned for single nucleotide polymorphisms 
(SNPs) that had been investigated in at least three studies. 
However, a meta-analysis was not performed due to the 
heterogeneity of the study characteristics and SNPs meas-
ured with very few replication studies. Where data was not 
available in the full-text, original authors were contacted. 
 
Results 
 
Summary of studies retrieved 
The search strategy identified 241 studies, of which, fol-
lowing cross-referencing and exclusions, 14 full-text arti-
cles were identified and included in the qualitative synthe-
sis (see Figure 1).     
 
Study characteristics 
The characteristics of the 14 studies are summarised in Ta-
ble 1. A total of 160 different polymorphisms in 27 genes 
were studied in 10,442 participants, of which 2,984 were 
marathon distance runners, 6,109 were non-athlete controls
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                 Figure 1. Flow diagram of the phases of study selection during the search process based on PRISMA. 
 
or 310 power athletes. Of the 160 polymorphisms, 159 
were collectively investigated in two studies (Tsianos et al., 
2010; He et al., 2015), where a total of 139 polymorphisms 
were studied in one paper alone by He et al., (2015). 
Where, the study investigated 84 polymorphisms in two 
genes, of which there were no reported associations (He et 
al., 2015). Only the ACE SNP I/D rs4646994 was investi-
gated in three studies (Amir et al., 2007; Ash et al., 2011; 
Tobina et al., 2010). Thirteen of the studies were case-con-
trol or cohort designs with only one applying the new 
GWAS approach (Ahmetov et al., 2015), although GWAS 
was not applied to the comparison of the athlete groups 
with the control groups. While 11 studies discovered at 
least one endurance-related allele, Ash et al. (2011), Saw-
czuk et al. (2013) and Papadimitriou et al. (2018) found no 
genetic association.  
Due to the heterogeneity of the study characteristics 
and SNPs measured with very few replication studies, it 
was deemed inappropriate to amalgamate the results for a 
meta-analysis. Therefore, the results in the current review 
were only analysed qualitatively.  
 
Risk of bias within studies 
The risk of bias of each study is presented in Table 2. Over-
all, the majority of studies were considered to have a “low” 
risk of bias in random sequence generation, allocation con-
cealment and blinding. However, “high” risk of bias arose 
from the domains of missing outcome data in both Döring 
et al. (2010) and Martinez et al. (2009) for whom addition-
ally, an “unclear” risk of bias arose from selective report-
ing of results. Two studies were also deemed “unclear” for 
missing outcome data (Ash et al., 2011; Posthumus et al., 
2011) and two “unclear” (Ahmetov et al., 2015; Myerson 
et al., 1999) for selective reporting of results. 
 
Results of individual studies 
Of the ten studies which compared the distribution of SNPs 
between elite endurance athletes (marathon runners n= 
1,832) with control groups (n= 6,109), eight found a sig-
nificant difference between the two groups (Table 3). No-
tably, the results for the ACE gene were heterogeneous. 
For example, while Tobina et al. (2010) found a strong as-
sociation between ACE I/D rs4646994 and elite endurance 
runners (p = 0.001; Table 1), Ash et al.  (2011) found no 
significant association (p = 0.16; Table 1). Of the 16 en-
durance-related alleles identified, nuclear factor I A-anti-
sense RNA 2 (NFIA-AS2) SNP rs1572312 C displayed the 
highest frequency among elite endurance athletes (95.5%), 
however, this study was limited to two elite marathon run-
ners (Ahmetov et al., 2015).  
Genes and elite marathon running 
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 Table 1. Characteristics of studies included (bold indicates gene of interest). 
References Participants    Study design Genes and SNPs measured Outcome(s) 
Ahmetov  
et al., 2015 
Russian endurance athletes (n= 
219; 2 marathon runners), power 
athletes (n=230), Russian controls 
(n=192) and European controls 
(n=1367) 
GWAS 
NFIA-AS2  rs1572312 C/A 
TSHR  rs7144481 T/C 
RBFOX1  rs7191721 G/A 
C alleles of NFIA-AS2 rs1572312 
and TSHR rs7144481 associated 
with elite endurance athlete status 
including marathon runners.  
Amir  
et al., 2007 
Israeli elite marathon runners 
(n=79), elite power athletes (n=42) 
and sedentary controls (n=247) 
Case-
control ACE I/D rs4646994 
D allele associated with elite mara-
thon athlete status.  
Ash  
et al., 2011 
Ethiopian elite endurance runners 
(n=76), demographically matched 
controls (n=410), controls from 
general Ethiopian population 
(n=317), power athletes (n=38) 
Case-
control 
ACE 
I/D rs4646994; 
A22982G rs4363 
No association with elite Ethiopian 
runners. 
Döring  
et al., 2010 
Caucasian male elite endurance ath-
letes (n=316; 39 runners) and Cau-
casian male sedentary controls 
(n=304) 
 
Case-
control 
HIF1A 
Pro582Ser;  rs11549465; 
C/T rs17099207 G/A; rs1951795 
C/A; rs11158358 C/G; rs2301113 
A/C; rs11549467 G/A 
Pro582 C allele of rs11549465 and 
A allele of rs17099207 associated 
with elite endurance runners. 
He  
et al., 2015 
Chinese elite endurance runners 
(n=235) and Chinese controls 
(n=504) 
Case-
control 
PPARAGCIα (41 SNPs) 
PPARAGCIβ (43 SNPs) 
PPRCI1 (4 SNPs); TFAM (3 SNPSs); 
TFB1M (7 SNPs); TFB2M (3 SNPs); 
NRF1 (14 SNPs); GABPA (2 SNPs); 
GABPA (5 SNPs); ERRα (4 SNPs); 
SIRT1 (7 SNPs) 
No significant association be-
tween proliferator-activated re-
ceptor γ (PGC)-related genes and 
elite endurance running status af-
ter adjusting for multiple compari-
sons. 
Martinez  
et al., 2009 
Hispanic marathon runners (n=784; 
393 3rd percentile and 388 lowest 
3rd percentile finishers) 
Case-
control AQP1 rs1049305 C/G 
C allele associated with elite perfor-
mance in Hispanic marathon runners. 
Myerson  
et al., 1999 
Elite runners (n=91; 79 Caucasian) 
and British controls (n=1906) 
Case-
control ACE I/D rs1049305 C/G 
I allele positively associated with elite 
endurance running performance. 
Papadimitriou 
et al., 2018 
1,5k, 3k, 5k, and 42k m running 
times of 698 male and female Cau-
casian endurance athletes 
Cohort ACTN3 R577X ACE I/D 
No association between ACTN3 or 
ACE I/D genotype and running perfor-
mance at any distance. 
Posthumus  
et al., 2011 
Caucasian male triathlon (incl. 
42.2km run) finishers (n=313) Cohort 
COL5A1 
BstUI RFLP rs12722 T/C 
T allele associated with faster time to complete 
running component (42.2km) of triathlon. 
Sawczuk  
et al., 2013 
Polish elite endurance athletes 
(n=123; 12 marathon runners) and 
sedentary controls (n=228) 
Case-
control ADRA2A rs553668 C/T 
No association with elite endurance athlete 
status including marathon runners. 
Stebbings  
et al., 2018 
Male marathon runners (n=141) 
and recreationally active men 
(n=137) 
Cohort TTN rs10497520 
TTN gene is associated with shorter skele-
tal muscle fascicle length and conveys an 
advantage for marathon running perfor-
mance in trained men. 
Tobina  
et al., 2010 
Japanese male elite endurance run-
ners (n=37) and non-athlete con-
trols (n=335) 
Case-
control ACE I/D rs4646994 
Frequency of the ACE I/D genotype was 
lower in elite endurance runners than con-
trols. The D allele was associated with 
faster marathon -running speed. 
Tsianos  
et al., 2010 
Greek Mount Olympus marathon 
runners (n=438) Cohort 
ACTN3 rs1815739 
AMPD1 rs17602729 
BDKRB2 rs1799722 
ADRB2 rs1042713 
PPARGC1α rs8192678 
PPARα rs4253778; rs6902123 
rs1053049; rs2267668 
APOE rs7412; rs429358 
BDKRB2 rs1799722, ADRB2 
rs1042713 and AMPD1 rs17602729 as-
sociated with endurance running perfor-
mance. 
Wolfarth  
et al., 2008 
Caucasian male elite endurance 
athletes (n=316; 39 runners) and 
sedentary male controls (n=299) 
Case-
control 
NOS3 Glu298Asp rsl799983 G/T 
(CA)n repeats; 27-bp repeats 4B/4A 
164 bp allele of (CA)n repeats asso-
ciated with elite endurance runners. 
NFIA-AS2, nuclear factor I A- antisense RNA 2;  TSHR, thyrotropin receptor precursor; RBFOX1, RNA binding protein fox-1 homolog;  ACE, angiotensin-
converting enzyme; HIF1A, hypoxia-inducible factor 1-alpha, PPARGC1α, peroxisome proliferator-activated receptor gamma coactivator 1-alpha; PPARGC1β, 
peroxisome proliferator-activated receptor gamma coactivator 1-beta; PPRC1, peroxisome proliferator-activated receptor gamma coactivator-related protein 1; 
TFAM, mitochondrial transcription factor A; TFB1M, mitochondrial transcription factor B1; TFB2M, mitochondrial transcription factor B2; NRF1, nuclear 
respiratory factor 1; GABPA, GA-binding protein transcription factor alpha; GABPB1, GA-binding protein transcription factor beta 1; ERRα, estrogen-related 
receptor alpha; SIRT1, sirtuin-1; AQP1, aquaporin 1; COL5A1, collagen type V alpha-1; ADRA2A, adrenergic receptor alpha 2A; ACTN3, alpha-actinin-3; 
AMPD1, adenosine monophosphate deaminase 1; BDKRB2, bradykinin receptor B2; ADRB2, adrenergic receptor beta 2; PPARα, peroxisome proliferator 
activated receptor alpha; PPARD, peroxisome proliferator activated receptor delta; APOE, apolipoprotein E; NOS3, nitric oxide synthase 3. 
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Table 2. Risk of bias assessment as analysed by the Cochrane risk of bias tool (Higgins et al., 2016). 
References Domain A Domain B Domain C Domain D Domain E Total 
Ahmetov et al., 2015 Low Low Low Low Unclear Low 
Amir et al., 2007  Low Low Low Low Low Low 
Ash et al., 2011 Low Low Low Unclear Low Low 
Döring et al., 2010 Low Low Low High Low Low 
He et al., 2015 Low Low Low Low Low Low 
Martinez et al., 2009 Low Low Low High High Unclear 
Myerson et al., 1999 Low Low Low Low Unclear Low 
Papadimitriou et al., 2018 Unclear Low Low Low Low Low 
Posthumus et al., 2011 Low Low Low Unclear Low Low 
Sawczuk et al., 2013 Low Low Low Low Low Low 
Stebbings et al., 2017 Low Low Low Low Low Low 
Tobina et al., 2010 Low Low Low Low Low Low 
Tsianos et al., 2010 Low Low Low Low Low Low 
Wolfarth et al., 2008 Low Low Low Low Low Low 
Definition of categories: Domain: (A) sequence generation; (B) allocation concealment; (C) blinding; (D) missing outcome data; (E) 
selective reporting of results. Total risk of bias grade calculated by assessing the five domains (A–E). 
 
Table 3. Allelic frequencies of the SNPs identified by comparison between elite endurance runners and controls. 
References  SNP Frequency of allele in elite 
endurance runners, % 
Frequency of  
allele in controls, % 
P-value 
Ahmetov et al., 2015 
NFIA-AS2 rs1572312 C 
TSHR rs7144481 C 
RBFOX1 rs7191721 G 
95.5 
25.7 
58.6 
88.8 
17.4 
56.3 
0.007* 
0.032* 
0 .60 
Amir et al., 2007 ACE D rs4646994 ACE DD rs4646994 
77.0 
62.0 
66.0 
43.0 
0.01* 
0.004* 
Ash et al., 2011 ACE I/D rs4646994 ACE A22982G rs4363 
44.7 
44.7 
45.6 
45.8 
0.16 
0.97 
Döring et al., 2010 
HIF1A Pro582 rs11549465 C  
HIF1A rs17099207 A 
HIF1A rs1951795 C 
HIF1A rs11158358 C/G 
HIF1A rs2301113 A/C  
HIF1A rs11549467 G/A 
84.0 
9.2 
67.7 
25.3 
33.5 
3.2 
75.0 
4.9 
62.2 
27.0 
32.9 
1.6 
0.017* 
0.045* 
0.038* 
0.07 
0.06 
0.21 
He et al., 2015 
PPARAGC1A rs4452416 T 
PPARAGC1B rs2161257 G 
NRF1 rs7794909 T 
SIRT1 rs11596401 C 
17.2 
39.6 
9.6 
87.2 
13.1 
33.6 
5.8 
83.3 
0.035* 
0.026* 
0.007* 
0.050* 
Martinez et al., 2009 AQP1 rs1049305 C 57.0 49.0 0.03* 
Myerson et al., 1999 ACE I rs4646994 52.0 49.0 0.01* 
Sawczuk et al., 2013 ADRA2A rs553668 C 85.8 82.9 0.40 
Tobina et al., 2010 ACE I/D rs4646994 44.0 44.0 0.001* 
Wolfarth et al., 2008 
NOS3 Glu298Asp rs1799983 G/T 
NOS3 (CA)n repeats 164 bp  
NOS3 27-bp repeats 4B/4A 
41.0 
24.1 
25.0 
47.0 
16.7 
25.0 
0.27 
0.01* 
0.83 
*Significant difference between elite endurance, including marathon runners, and controls at p < 0.05 level. 
 
Another four studies evaluated the association of 
SNPs with marathon running performance as opposed to 
athlete status.  Posthumus et al. (2011) demonstrated a sig-
nificant association between the collagen type V alpha-1 
(COL5A1) gene BstUI RFLP T/C (rs12722) polymor-
phism and time to complete the running component of a 
triathlon where participants with a TT genotype completed 
the 42.2km run significantly faster than those with a CC 
genotype (p = 0.019). 
Tsianos et al. (2010) found a significant association 
between beta-2 adrenergic receptor (ADRB2) SNP 
rs1042713 and adenosine monophosphate deaminase 1 
(AMPD1) SNP rs17602729 and the fastest reported mara-
thon completion times among male athletes (p = 0.01 and 
p = 0.04, respectively). In addition, among the whole male  
cohort, and all the more so when limited to habitual male 
runners, bradykinin B2 receptor (BDKRB2) SNP 
rs1799722 significantly deviated from Hardy-Weinberg 
equilibrium with an excess of the TT genotype (18.8%) 
which may indicate an associated genotype to endurance 
performance.  
Additionally, Stebbings et al. (2018) found a signif-
icant difference in personal running time between titin 
(TTN) CC homozygote and CT heterozygote carriers in 
trained marathon runners (p = 0.02). However, Papadi-
mitriou et al. (2018) did not find any significant association 
between alpha-actinin-3 (ACTN3) R577X or ACE I/D pol-
ymorphisms and endurance running times in a sample of 
698 Caucasian athletes, so that an influence on running per-
formance based on these two genes cannot be assumed. 
 
Genes and elite marathon running 
  
 
564 
Discussion 
 
In the present review, data from 3,889 elite endurance ath-
letes; 2,984 of which were specified as marathon runners, 
and 6,109 control individuals were qualitatively synthe-
sised to evaluate the contribution and role of identified pol-
ymorphisms and genes to differentiate elite marathon per-
formance from non-elite, power athletes and controls. Ad-
vancing previous systematic reviews which had focused 
solely on the candidate genes ACE and PPARα (Ma et al., 
2013; Lopez-Leon et al., 2016), the results of the current 
review demonstrated that the following 16 SNPs in 14 dif-
ferent genes may be associated with elite marathon running 
performance:  
NFIA-AS2 rs1572312 C, thyrotropin receptor pre-
cursor (TSHR)  rs7144481 C, ACE rs4646994 I/D, hy-
poxia-inducible factor 1-alpha (HIF1A) Pro582 
rs11549465 C, HIF1A rs17099207 A, HIF1A rs1951795 
C, PPARAGC1α rs4452416 T, PPARAGC1β rs2161257 
T, nuclear respiratory factor 1 (NRF1) rs7794909 C, 
sirtuin-1 (SIRT1) rs11596401 C, aquaporin (AQP1) 
rs1049305 C, nitric oxide synthase 3 (NOS3) (CA)n repeats 
164 bp, COL5A1 BstUI RFLP rs12722 T, ADRB2 
rs1042713, AMPD1 rs17602729 and BDKRB2 rs1799722.  
These findings provide support for the role of mul-
tiple endurance-related genes and are in line with previous 
literature that has reported that at least 93 genetic markers 
are associated with elite endurance athlete status in general 
(Ahmetov et al., 2016).  
 
Key primary functions of identified genes 
Although a detailed mechanistic explanation regarding the 
roles of each of the identified genes and their polymor-
phisms in elite marathon running performance is beyond 
the scope of this review, the following points can be noted.  
Of the fourteen genes, the PPARAGC1α, 
PPARAGC1β, NRF1, SIRT1, HIF1A, AQP1, AMPD1, 
BDKRB2, NFIA-AS2 and TSHR genes code for transcrip-
tion factors and coactivators primarily involved in meta-
bolic pathways (i.e. adenosine triphosphate (ATP) genera-
tion, glucose and lipid metabolism, mitochondrial biogen-
esis, thermogenesis, angiogenesis and muscle fibre type 
composition).  
The COL5A1 gene encodes type V collagen in lig-
aments and is involved in range of motion (Brown et al., 
2011) and COL5A1 rs12722 may influence the energetic 
cost of running (Posthumus et al., 2011).  
The ACE, NOS3 and ADRB2 genes code for en-
zymes involved in cardiovascular function such as blood 
pressure and vasodilation (Wolfarth et al., 2008; Ahmetov 
et al., 2009; Drozdovska et al., 2013).  
In particular, the PPARAGC1α and PPARAGC1β 
genes have been suggested to play a key role in exercise-
induced mitochondrial biogenesis through the co-activa-
tion of NRF1 (Joseph et al., 2006). In turn, NRF1 induces 
the transcription of mitochondrial transcription factor A 
(TFAM) resulting in mitochondrial DNA (mtDNA) repli-
cation (Yan et al., 2010). By increasing mitochondrial con-
tent, marathon running performance may be improved due 
to increased beta-oxidation resulting in the conservation of 
glycogen  stores  and  reduction  in  lactate   accumulation  
(Cantó et al., 2009).  
Interestingly, it has been proposed that the activity 
of PPARAGC1α during endurance exercise is regulated by 
another of the identified genes SIRT1 (Philp et al., 2013). 
The AMP-activated protein kinase (AMPK)-induced acti-
vation of SIRT1 results in the deacetylation of 
PPARAGC1α, which in turn increases PPARAGC1α ac-
tivity and upregulates mitochondrial biogenesis in skeletal 
muscle (Cantó et al., 2009). Therefore, SIRT1 may also be 
beneficial in marathon running performance due to its abil-
ity to deacetylate PPARAGC1α in a nicotinamide adenine 
dinucleotide (NAD+) dependent manner (Nemeto et al., 
2005).  
In addition, PPARAGC1α has been shown to stim-
ulate the formation of type I slow-twitch fibres (Lin et al., 
2002). This increased proportion of oxidative slow-twitch 
fibres is likely to improve marathon running performance 
as it is related to a higher oxidative capacity, mitochondrial 
content and fatigue resistance (Hawley and Spargo, 2007). 
Accordingly, Ahmetov et al. (2009) demonstrated that the 
PPARAGC1α rs8192678 polymorphism was positively as-
sociated with the percentage of slow-twitch fibres,  Vሶ O2 
max and elite endurance athlete status.  
Conversely, in the present review, no association 
was found between PPARAGC1α rs8192678 and elite 
marathon running performance (p = 0.64; Tsianos et al., 
2010). However, other allelic variants in the gene such as 
rs4452416 T were associated with elite endurance running 
status (p = 0.035; He et al., 2015). One possible explana-
tion for the differences between the results of the current 
review and previous studies (Ahmetov et al., 2009; Tural 
et al., 2014) is the ethnicity of the population investigated. 
It has been demonstrated that a significant association be-
tween polymorphic variants and elite sport performance 
observed in one population is not always replicated in other 
populations (Ginevičienė et al., 2011). Therefore, the pos-
sibility cannot be excluded that the lack of association be-
tween PPARAGC1α rs819268 polymorphism and mara-
thon running performance found by Tsianos et al. (2010) 
was distinctive to athletes of Greek ancestry.  
Although studies set the per-allele effect typically 
at 80% power to detect at α= 0.05 associations (Tsianos et 
al., 2010), a small effect size could still remain and inter-
individual differences in endurance performance may be 
influenced by genetic variations that may not be identified 
or consistently replicated at a genome-wide level (Papadi-
mitriou et al., 2018). In genetic association studies, there is 
still uncertainty due to lack of statistical power, unknown 
connection with other variants and environmental interac-
tions. Therefore, it cannot exclude the possibility that the 
associations are due to type 1 error or an unknown connec-
tion to another polymorphic functional variant (Döring et 
al., 2010). 
The AQP1 rs1049035 C/G polymorphism (Mar-
tinez et al., 2009) encodes a water channel protein, which 
has been suggested to play a key role in the regulation of 
body temperature and the secretion and absorption of body 
fluid (Sui et al., 2001). During osmotic stress (i.e. endur-
ance exercise), AQP1 facilitates the transport of water from 
the blood into the muscle and promotes water reabsorption 
(Sui et al., 2001). In support of this, carriers of the AQP1 
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rs1049305 C allele had a significantly greater adjusted 
body fluid loss (3.7 ± 0.9 kg) than non-carriers (1.5 ± 1.1 
kg) in response to a 10km distance run (p < 0.05; Rivera et 
al., 2011). Therefore, the possession of the AQP1 
rs1049305 C allele may enhance marathon running perfor-
mance due to the maintenance of adequate body fluid bal-
ance, thereby improving blood flow and enhancing oxygen 
delivery to the working muscles and thermoregulation 
(Brooks et al., 2005). 
The HIF1A gene functions as a master regulator of 
oxygen homeostasis and has been suggested to play a role 
in a number of cellular functions including angiogenesis, 
erythropoiesis and glucose metabolism (Ahmetov et al., 
2009). The ability of HIF1A protein to inhibit ubiquitina-
tion and proteasomal degradation under hypoxic condi-
tions results in an exponential increase in HIF1A levels as 
cellular oxygen concentration decreases, which in turn 
stimulates erythropoiesis and consequently improves the 
efficiency of oxygen delivery to the working muscles (Si-
menza, 2002). Furthermore, the HIF1A polymorphism 
Pro582 rs11549465 C has been associated with both a 
higher initial value and trainability of Vሶ O2 max (Prior et al., 
2003) which is an important factor governing the capacity 
of marathon running performance (Joyner and Coyle, 
2008).  
With regard to the role of genes involved in cardio-
vascular functions, ACE has been the most extensively 
studied candidate gene (Ahmetov et al., 2009). It plays a 
key role in the regulation of blood volume and pressure by 
promoting the synthesis of vasoconstrictor angiotensin II 
(ANG II) and the degradation of vasodilator kinins (Woods 
et al., 2000). The I allele has been proposed to improve en-
durance performance due to lower ACE activity and in-
creased bradykinin levels resulting in enhanced substrate 
delivery to the working muscles (Woods et al., 2000). In 
support of this, the present review found a positive associ-
ation between the ACE polymorphism I rs4646994 and en-
durance running performance (Myerson et al., 1999). In 
contrast, two of the studies (Amir et al., 2007; Tobina et 
al., 2010) found that the D allele was favourable for elite 
marathon running performance. It is speculated that the D 
allele may result in improved cardiac function due to its 
association with increased exercise-induced left ventricular 
hypertrophy (Hernández et al., 2003).  
In addition, the higher ACE activity associated with 
the D allele in comparison to the I allele, may hinder glu-
cose uptake in skeletal muscle due to the increased degra-
dation of bradykinin, a trigger for glucose transporter type 
4 (GLUT4) translocation, predominantly expressed in the 
muscle (Kishi et al., 1998). This may be advantageous to 
marathon running performance as this regulates glucose 
homeostasis, allowing glucose uptake, thereby preventing 
hypoglycaemia and central fatigue (Newsholme et al., 
1992). Moreover, Ash et al. (2011) found no association 
between ACE gene variation and East African elite mara-
thon runners. These discrepancies highlight the limitations 
of the interpretation of association studies and may be at-
tributable to sample sizes, ethnic disparities and the inclu-
sion of athletes from a heterogeneous range of endurance 
sporting disciplines (Barley et al., 1994; Rankinen et al., 
2000). 
Risk of bias and reasons for divergent results  
Despite the wide variety of genetic markers included in the 
present review, it should be emphasised that only one of 
the 160 SNPs, ACE I/D rs4646994, was investigated in 
three (Amir et al., 2007; Ash et al., 2011; Tobina et al., 
2010). The lack of replicated studies raises the possibility 
that some of the results reported might be false-positive 
and highlights the infancy of the field of sport genomics. It 
is also important to highlight the impact of epigenetics, in 
which the environment influences the expression of genes. 
Of relevance, Raleigh (2012) highlights the implications of 
epigenetic factors on the regulation of the ACE gene be-
yond that of the I/D polymorphisms. As such, in addition 
to genotyping, understanding the impact of epigenetic reg-
ulation on genes such as ACE and the modification to en-
durance performance is of paramount importance. 
As a consequence of limited replication of geno-
type-phenotype associations, the significant associations in 
the small candidate gene studies observed in 8 out of the 
10 studies that compared elite athletes to control groups, 
illustrates a possible publication bias. Therefore, robust 
replication of studies in large cohorts of athletes is required 
before findings can be applied to practice in sport.  
Furthermore, much of the existing research as-
sessing the role of genes in sport performance has focused 
on endurance or power/strength as a whole (Ahmetov et al., 
2016), which was evident in the present review with only 
four of the studies (Amir et al., 2007; Martinez et al., 2009; 
Tsianos et al., 2010; Ash et al., 2011) solely including elite 
marathon runners. The inclusion of different sporting dis-
ciplines in the majority of the studies identified a potential 
limitation as it dilutes the phenotypic characteristics and 
selection of elite athletes (Williams et al., 2014). Therefore, 
further empirical attention within a given sport, in this case 
marathon running, is required. The application of genomic 
data to practice in sport is currently considered premature, 
thus the second objective of this review, to provide some 
insight into the use of genetic testing in marathon talent 
identification was not achievable. 
Although the overall risk of bias within the included 
studies was deemed low, some areas of concern included 
selective reporting bias and incomplete data. In particular, 
studies tended to only report the allelic frequencies of the 
most significant SNPs identified (Ahmetov et al., 2015). 
Therefore, it is recommended that future studies report all 
allelic frequencies measured rather than solely focusing on 
the most common genetic variants. It is envisaged that by 
moving away from the candidate gene approach a greater 
understanding of the polygenic nature of performance-re-
lated physical and mental traits will be established.  
The lack of significant association in many studies 
despite the large number of SNPs included indicates how 
difficult it is to identify genes that influence the status of 
being a world-class elite athlete (He et al., 2015). This is 
likely due to the presence of small scale studies, the lack of 
replication of genotype-phenotype associations and the 
likelihood of publication bias. Future replication studies, 
however, are needed to determine if functional SNPs con-
tribute to the wide variability in athletic performance and 
adaptation to endurance training (He et al., 2015).  
To fully understand the mechanisms underlying the  
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supposed association between polymorphisms and endur-
ance performance, these functional studies are required. A 
GWAS approach may be warranted since this has been 
suggested to be advantageous in the detection of multiple, 
novel genetic variants due to its whole-genome analysis 
and hypothesis-free approach (Pitsiladis et al., 2013). 
Where GWAS has already shown success in elucidating 
the genetic basis for other complex traits such as obesity 
and Type II diabetes mellitus (Frayling et al., 2007; 
McCarthy and Zeggini, 2009). However, it cannot be ig-
nored, that candidate genes have at times yielded reproduc-
ible outcomes, and thus GWAS may be used as an ap-
proach to identifying genetic variants to be followed by 
candidate gene studies. Additionally, the impact of epige-
netics and therefore the role of environmental factors are 
also of importance to understanding the phenotype of mar-
athon running and cannot be excluded from establishing 
the role and impact genes play in the success of sport per-
formance.  
 
Implications  
In addition to the above-discussed natural influence of ge-
netic differences on running performance, a potential risk 
and ethical issue has emerged by the manipulation of such 
genes to enhance physical performances through gene dop-
ing. Commonly defined as the transfer of genes or genet-
ically modified cells into an individual as a potential 
method to illicit athletic performance enhancement. Gene 
doping is considered an arising and upcoming threat to 
clean sport and a prohibition of gene doping methods was 
added to the World Anti-Doping Agency (WADA) prohib-
ited list since 2003, but although there are no known cases 
of gene doping use among high performance athletes as 
yet, the application of gene manipulation in sports cannot 
be ruled out (Haisma and De Hon, 2006).  
Van der Gronde (2013) reviewed and assessed the 
usability of known human performance-related genes for 
the potential as a gene doping substances. Ultimately, pe-
roxisome proliferator-activated receptor-delta (PPAR) 
and cytosolic phosphoenolpyruvate carboxykinase 
(PEPCK-C) were identified as high potential genes for 
abuse. However, to date, genetic science especially in 
terms of doping is in its infancy and therefore prone to un-
known risks and linked to a high degree of potentially life-
threatening dangers (Miah, 2004). Furthermore, a deliber-
ate intervention into human genetics to enhance physical 
capacities goes against the notion and ethical aspects of 
sport as fair competition, just as conventional doping such 
as steroid use does (Breivik, 2005). 
 
Conclusion 
 
In conclusion, to the author’s knowledge this is the first 
systematic review investigating the role of multiple genetic 
markers in elite marathon running performance. Overall, a 
possible 16 different SNPs in 14 genes have been identi-
fied, which can be used as preliminary evidence for devel-
oping focused investigation of the polygenic nature of 
complex endurance-related traits.  
It is still unknown which genes are specifically as-
sociated  to  elite  marathon  performance  due  to the small  
effect sizes, and that the variants of interest are not likely 
to be obligatory. Also limited replication of genotype-phe-
notype associations and possible publication bias exists, 
thus further studies are required to strengthen our under-
standing of the genes involved in elite marathon running. 
As a result, future research adopting the GWAS approach 
is warranted for the detection of multiple, novel genetic 
variants. Therefore, as the science of sport genomics ma-
tures through the utilisation of genome-wide technologies 
over the coming years there is potential for the use of ge-
netic testing as a valid tool in the identification of young 
athletes. This early identification of potential physical and 
mental traits is of paramount interest to optimise training 
and marathon running performance but is also a potential 
threat to the integrity of sport, with the potential of gene 
doping.  
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Key points 
 
 Elite marathon running has a polygenic nature of com-
plex endurance-related traits.  
 There is limited replication of genotype-phenotype as-
sociations to currently determine the genes involved 
in marathon running.  
 Genome-wide technologies in large cohorts are re-
quired to elucidate the multiple genetic factors that 
govern the complex endurance-related traits of mara-
thon running and the impact of epigenetics should be 
considered. 
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